Multiply Labs Raises $75M in Series B Funding to Scale Robotic Drug Manufacturing

{
  "signal_id": "4f09bc0d-59a7-067a-2e39-4444c415c035",
  "signal_type": "news",
  "signal_subtype": "invests_into",
  "detected_at": "2026-09-17T01:25:50+00:00",
  "company": {
    "name": "AstraZeneca",
    "domain": "astrazeneca.com"
  },
  "data": {
    "url": "https://theaiinsider.tech/2026/09/17/multiply-labs-raises-75m-in-series-b-funding-to-scale-robotic-drug-manufacturing/",
    "title": "Multiply Labs Raises $75M in Series B Funding to Scale Robotic Drug Manufacturing - AI Insider",
    "excerpt": "Insider Brief Multiply Labs has raised $75 million in Series B funding to expand its robotic manufacturing platform for cell and gene therapies and other advanced biologics. The round brings the San Francisco company’s total funding to more than $100 million since its founding in 2016. AstraZeneca Ventures, Lingotto, Legend Biotech and Strange Ventures joined returning investors Casdin Capital, Lux Capital and Founders Fund in leading the round, according to Multiply Labs. The company indicated it plans to use the capital to expand manufacturing capacity, speed up product development and grow its engineering, regulatory and commercial teams as it goes from clinical-stage deployments toward commercial-scale production. Multiply Labs noted the problem in the manufacturing process is that it remains largely manual even as artificial intelligence accelerates drug discovery. The company said contamination during biomanufacturing can cost millions of dollars and delay access to treatments, creating pressure to increase production capacity as more therapies move through development. The company, founded in 2016 as a Y Combinator startup, builds robotic clusters that work with pharmaceutical manufacturers’ existing instruments and processes without requiring new facilities or changes to already validated practices. Each enclosed system automates timed and repetitive steps in biologics...",
    "summary": "AstraZeneca Ventures participated in Multiply Labs' $75 million Series B funding round.",
    "location": "San Francisco, California, USA",
    "planning": false,
    "confidence": 0.8,
    "published_at": "2026-09-17T01:25:50Z",
    "location_data": [
      {
        "city": "San Francisco",
        "state": "California",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "AstraZeneca Ventures, Lingotto, Legend Biotech and Strange Ventures joined returning investors Casdin Capital, Lux Capital and Founders Fund in leading the round, according to Multiply Labs.",
    "financing_type_tags": [
      "equity"
    ],
    "related_company_name": "Multiply Labs",
    "related_company_domain": "multiplylabs.com",
    "financing_type_normalized": "series_b"
  }
}

curl https://signals.autobound.ai/v1/signals/4f09bc0d-59a7-067a-2e39-4444c415c035 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"astrazeneca.com","limit":20}'